Results 111 to 120 of about 80,296 (266)

Red lines and green lights: Gene therapy for inherited erythroid disorders beyond the haemoglobinopathies

open access: yesBritish Journal of Haematology, EarlyView.
Gene therapy is revolutionizing treatment paradigms for haemoglobinopathies, establishing a translational framework for disorders that impact red blood cell development. In their paper, Joshi et al. describe the preclinical and early clinical landscape of gene therapies for non‐haemoglobinopathy erythroid disorders and highlight common thematic ...
Gaurav Joshi   +3 more
wiley   +1 more source

Prognostic impact of blood Epstein–Barr virus‐DNA in patients with peripheral T‐cell lymphoma, not otherwise specified

open access: yesBritish Journal of Haematology, EarlyView.
Summary Peripheral T‐cell lymphoma, not otherwise specified (PTCL‐NOS), is a heterogeneous nodal T‐ and natural killer (NK)‐cell lymphoma with limited prognostic biomarkers. A subset of PTCL‐NOS characterized by Epstein–Barr virus (EBV) involvement in tumour cells has recently been recognized as EBV‐positive nodal T‐ and NK‐cell lymphoma (EBV+ nPTCL ...
Hyunseok Yoon   +14 more
wiley   +1 more source

Compartmentalisation in cAMP signalling: A phase separation perspective

open access: yesBritish Journal of Pharmacology, EarlyView.
Cells rely on precise spatiotemporal control of signalling pathways to ensure functional specificity. The compartmentalisation of cyclic AMP (cAMP) and protein kinase A (PKA) signalling enables distinct cellular responses within a crowded cytoplasmic space.
Milda Folkmanaite, Manuela Zaccolo
wiley   +1 more source

Covalent drug discovery: Progress against key targets, emerging strategies and lessons learnt

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Covalent drug discovery is currently experiencing a boom in industrial and academic interest. To date, at least 75 covalent drugs have received regulatory approval, targeting both traditional target classes and more challenging proteins for which other approaches failed. In many cases, unique aspects of covalent targeting are essential for the
Charles P. Brown   +2 more
wiley   +1 more source

Spatial Transcriptomics and Bulk RNA‐Seq Analysis Revealed Molecular Classification of Invasive Lobular Carcinoma

open access: yesCancer Science, EarlyView.
Spatial transcriptomics and bulk RNA‐seq data analysis revealed the molecular characteristics of invasive lobular carcinoma (ILC). ILC was classified into three clusters: proliferative, immunoreactive, and stromal‐rich, with different prognoses. ABSTRACT Invasive lobular carcinoma (ILC) is a special type of breast cancer.
Momoko Tokura   +9 more
wiley   +1 more source

A Three‐Dimensional Culture–Drug Sensitivity Test Predicts MDM2 Inhibitor–Sensitivity in SMARCB1/INI1‐Deficient Tumors

open access: yesCancer Science, EarlyView.
This study aimed to determine whether personalized selection of effective drugs for SMARCB1/INI1‐deficient tumors is feasible using in vitro drug sensitivity profiling. Drug sensitivity was assessed using a short‐term collagen gel–embedded three‐dimensional drug sensitivity test (3D‐DST) in tumors derived from SMARCB1/INI1‐deficient tumor cell line ...
Hiroaki Goto   +12 more
wiley   +1 more source

Genetic Evolution in BRCA1‐Associated Breast Cancer Reveals Early Driver Mutations Shaping Tumor Features and Prognosis

open access: yesCancer Science, EarlyView.
Multi‐region sequencing of 57 BRCA1‐associated breast cancers identified TP53 as the dominant initial driver, defining a triple‐negative subgroup with biallelic BRCA1 loss and elevated genomic instability. TP53 truncating mutations were enriched in BRCA1 carriers and linked to reduced HRD, EMT activation, and a trend toward worse survival.
Li Hu   +13 more
wiley   +1 more source

Editorial Expression of Concern: Estrogen receptor β activation impairs mitochondrial oxidative metabolism and affects malignant mesothelioma cell growth in vitro and in vivo. [PDF]

open access: yesOncogenesis
Manente AG   +12 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy